Abstract
Biphasic effects of cannabinoids have been shown in processes such as feeding behavior, motor activity, motivational processes and anxiety responses. Using two different tests for the characterization of anxiety-related behavior (elevated plus-maze and holeboard), we first identified in wild-type C57BL/6N mice, two doses of the synthetic CB1 cannabinoid receptor agonist CP-55,940 with anxiolytic (1 μg/kg) and anxiogenic properties (50 μg/kg), respectively. To clarify the role of CB1 receptors in this biphasic effect, both doses were applied to two different conditional CB1 receptor knockout (KO) mouse lines, GABA-CB1-KO (CB1 receptor inactivation in forebrain GABAergic neurons) and Glu-CB1-KO (CB1 receptor inactivation in cortical glutamatergic neurons). We found that the anxiolytic-like effects of the low dose of cannabinoids are mediated via the CB1 receptor on cortical glutamatergic terminals, because this anxiolytic-like response was abrogated only in Glu-CB1-KO mice. On the contrary, the CB1 receptor on the GABAergic terminals is required to induce an anxiogenic-like effect under a high-dose treatment because of the fact that this effect was abolished specifically in GABA-CB1-KO mice. These experiments were carried out in both sexes, and no differences occurred with the doses tested in the mutant mice. Interestingly, the positive allosteric modulation of GABAB receptor with GS-39783 was found to largely abrogate the anxiogenic-like effect of the high dose of CP-55,940. Our results shed new light in further understanding the biphasic effects of cannabinoids at the molecular level and, importantly, pave the way for the development of novel anxiolytic cannabinoid drugs, which may have favorable effect profiles targeting the CB1 receptor on glutamatergic terminals.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bellocchio L, Lafenêtre P, Cannich A, Cota D, Puente N, Grandes P et al (2010). Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13: 281–283.
Biermann B, Ivankova-Susankova K, Bradaia A, Abdel Aziz S, Besseyrias V, Kapfhammer JP et al (2010). The Sushi domains of GABAB receptors function as axonal targeting signals. J Neurosci 30: 1385–1394.
Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M et al (2002). International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid (B) receptors: structure and function. Pharmacol Rev 54: 247–264.
Cryan JF, Kaupmann K (2005). Don’t worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 26: 36–43.
Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K et al (2004). Behavioral charcterizitaion of the novel GABAB receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or nezodiazepines. J Pharmacol Exp Ther 310: 952–963.
De Chiara V, Errico F, Musella A, Rossi S, Matalauni G, Sacchetti L et al (2010). Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35: 374–387.
El Manira A, Kyriakatos A (2010). The role of endocannabinoid signaling in motor control. Physiology 25: 230–238.
File SE, Wardill AG (1975). Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacologia 44: 53–59.
Gassmann M, Shaban H, Vigot R, Sansig G, Haller C, Barbieri S et al (2004). Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J Neurosci 24: 6086–6097.
Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004). Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 77: 567–573.
Grewal SS, Shepherd JK, Bill DJ, Fletcher A, Dourish CT (1997). Behavioural and pharmacological characterization of the canopy stretched attend posture test as a model of anxiety in mice and rats. Psychopharmacology 133: 29–38.
Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395–1408.
Haller J, Varga B, Ledent C, Barna I, Freund TF (2004). Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19: 1906–1912.
Häring M, Kaiser N, Monory K, Lutz B (2011). Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration. PLoS One 6: e26617.
Hernández-Tristán R, Arévalo C, Canals S, Leret ML (2000). The effects of acute treatment with Δ9-THC on exploratory behavior and memory in the rat. J Physiol Biochem 56: 17–24.
Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT (2009). Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 8: 685–698.
Jacobson LH, Cryan JF (2008). Evaluation of the anxiolytic-like profile of the GABAB receptor positive allosteric modulator CGP7930 in rodents. Neuropharmacology 54: 854–862.
Kamprath K, Plendl W, Marsicano G, Deussing JM, Wurst W, Lutz B et al (2009). Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 8: 203–211.
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309–380.
Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923–930.
Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M et al (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991–3001.
Koek W, France CP, Cheng K, Rice KC (2010). GABAB receptor-positive modulators: enhancement of GABAB receptor agonist effects in vivo. J Pharmacol Exp Ther 335: 163–171.
Lafenêtre P, Chaouloff F, Marsicano G (2009). Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid. Neuropharmacology 57: 715–721.
Lee SH, Foldy C, Soltesz I (2010). Distinct endocannabinoid control of GABA release at perisomatic and dendritic synapses in the hippocampus. J Neurosci 30: 7993–8000.
Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180–185.
Maldonado R (2002). Study of cannabinoid dependence in animals. Pharmacol Ther 95: 153–164.
Marco EM, Pérez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E et al (2004). Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 15: 21–27.
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84–88.
Marsicano G, Lutz B (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213–4225.
Massa F, Mancini G, Schmidt H, Steindel F, Mackie K, Angioni C et al (2010). Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci 30: 6273–6281.
McDonald AJ, Mascagni F, Muller JF (2004). Immunocytochemical localization of GABABR1 receptor subunits in the basolateral amygdale. Brain Res 1018: 147–158.
Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF (2004). Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29: 1050–1062.
Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G et al (2007). Genetic dissection of behavioural and autonomic effects of Δ9-tetrahydrocannabinol in mice. PLoS Biol 5: e269.
Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R et al (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455–466.
Moreira FA, Aguiar DC, Terzian AL, Guimarães FS, Wotjak CT (2012). Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 204: 186–192.
Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, Carrera MR et al (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 20: 491–496.
Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M (2002). Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 22: 3864–3872.
Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76: 1307–1324.
Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009). Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12: 1152–1158.
Roberto M, Cruz M, Bajo M, Siggins GR, Parsons LH, Schweitzer P (2010). The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala. Neuropsychopharmacology 35: 1962–1972.
Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G et al (2008). Chronic psychoemotional stress impairs cannabinoid-receptor control of GABA transmission in the striatum. J Neurosci 28: 7284–7292.
Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P et al (2008). CB1 receptor activation in specific brain areas differently modulates anxiety-related behavior. Neuropharmacology 54: 151–160.
Ruehle S, Aparisi Rey A, Remmers F, Lutz B (2012). The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26: 23–39.
Slanina KA, Schweitzer P (2005). Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. Neuropharmacology 49: 653–599.
Steindel F, Häring M, Marsicano B, Lutz B, Monory K (2008). Differential coupling of G proteins to CB1 receptors in hippocampal glutamatergic and GABAergic neurons. 18th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society. p. 119.
Urwyler S, Gjoni T, jatiæ J, Dupuis DS (2005). Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 48: 343–353.
Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W et al (2003). N-N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acid B receptor function. J Pharmacol Exp Ther 307: 322–330.
Viveros MP, Marco EM, File SE (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331–342.
Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A et al (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145: 293–300.
Acknowledgements
We wish to thank Yasmin Abassi, Krisztina Monory and Nadine Kaiser for discussion and excellent support in the experiments, Professor Bernhard Bettler for the helpful advices regarding the pharmacology of GABAB receptors, and Andrea Conrad and Danuta Dormann for the genotyping. This work was supported in part by the Hübner Foundation and the Deutschen Forschungsgemeinschaft (DFG) to BL (SPP1226; SFB TRR 58 TP A04).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
Rights and permissions
About this article
Cite this article
Rey, A., Purrio, M., Viveros, MP. et al. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacol 37, 2624–2634 (2012). https://doi.org/10.1038/npp.2012.123
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2012.123
Keywords
This article is cited by
-
Pharmacological diacylglycerol lipase inhibition impairs contextual fear extinction in mice
Psychopharmacology (2024)
-
Behavioral, biochemical and histopathological toxic profiles induced by sub-chronic cannabimimetic WIN55, 212–2 administration in mice
BMC Pharmacology and Toxicology (2023)
-
PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice
Molecular Psychiatry (2023)
-
Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson’s Disease: A Novel and Futuristic Approach
Neurotoxicity Research (2023)
-
Induction of Anxiety-Like Phenotypes by Knockdown of Cannabinoid Type-1 Receptors in the Amygdala of Marmosets
Neuroscience Bulletin (2023)
